Abstract：Objective: To study curative efficacy of pramipexole combined with benserazide tablets in treatment of parkinson's disease and effects on serum brain derived neurotrophic factor(BDNF), 5-serotonin (5-HT) and norepinephrine (NE) level. Methods: 100 patients of parkinson's disease who received therapy from June 2015 to June 2017 in our hospital were selected as research objects, according to random number table, those patients were divided into the observation group (n=50) and the control group (n=50). The control group was treated with benserazide tablets, while the observation group was combined with pramipexole. All the patients were treated continuously for 12 weeks. The clinical effects, Parkinson's unified score scale (UPDRS) score, serum BDNF, 5-HT, NE and adverse reactions of two groups were compared. The clinical effects of two groups were compared with the Parkinson unified score scale (UPDRS), and the enzyme linked immunosorbent assay was used to detect serum BDNF, 5-HT and NE, and the adverse reactions of the two groups were recorded. Results: After treatment, the total effective rate of clinical efficacy in the observation group was 94% (47/50), which was significantly higher than that of the control group 76% (38/50) (P<0.05); after treatment, the scores of UPDRS I, UPDRSⅡ, UPDRS Ⅲ, UPDRS Ⅳ and UPDRS total score of two groups were significantly lower than those before treatment (P<0.05), and the scores of UPDRS I, UPDRSⅡ, UPDRS Ⅲ, UPDRS Ⅳ and UPDRS total score in the observation group were significantly lower than that of the control group (P<0.05); after treatment, the serum BDNF, 5-HT and NE in the two groups were significantly higher than those before the treatment (P<0.05), and the serum BDNF, 5-HT and NE in the observation group were significantly higher than that of the control group (P<0.05); there was no significant difference in the incidence of nausea, vomiting, sleeplessness, upper abdominal discomfort and visual abnormality during the treatment of the two groups (P>0.05). Conclusion: Pramipexole combined with benserazide tablets is well for parkinson's disease, which can effectively improve the clinical effect, and its internal mechanism may be related to the increase of the expression of serum BDNF, 5-HT and NE.
[1] 刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98~101. [2] Sampaio TB, Savall AS, Gutierrez MEZ, et al. Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy[J]. Neural Regen Res, 2017, 12(4): 549~557. [3] 吴煜,邹显巍,罗嫚.帕金森病治疗的新进展[J].河北医学,2017,23(9):1573~1577. [4] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第3版)[J].中华神经科杂志,2014,47(6):428~433. [5] Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA[J].Neurol Neurosurg Psychiatry, 2004, 75(3): 388~395. [6] 张轶美,刘霄,王艳.普拉克索联合美多芭治疗晚期帕金森病的临床效果分析[J].中国实用医药,2018(2):103~104. [7] Motamedi S, Karimi I, Jafari F. The interrelationship of metabolic syndrome and neurodegenerative diseases with focus on brain-derived neurotrophic factor (BDNF): Kill two birds with one stone[J]. Metab Brain Dis, 2017, 32(3): 651~665. [8] 曹健,张谨,吕书轩,等.中缝背核内5-HT1受体在帕金森病中的调节作用[J].海南医学,2017,28(11):1816~1818. [9] Farrand AQ, Helke KL, Gregory RA, et al. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease[J]. Brain Stimul, 2017, 10(6): 1045~1054. [10] Shen T, Ye R, Zhang B. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials[J]. Eur Neurol, 2017, 24(6): 835~843.
2018, Vol. 24 
冀公网安备13080202000677号